Recent studies show that PLK1 and KIF4A as biomarkers have a high prognosis value in patients with prostate cancer (Gao et al., 2018; Cao et al., 2020; Liu et al., 2020; Wu et al., 2020; Das et al., 2021). Here, PLK1 is linked to prostate carcinoma.